Autopsy report · NCT01058759

Taxotere-Enoxaparin-(ENOXA)-Study

“The external funding (pharmaceutical company) was stopped and could not be substituded by internal funding.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 1 year 3 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hannover Medical School

Sponsor type

University, hospital or other

Conditions

Non-small Cell Lung Cancer

Interventions

Enoxaparin; No Enoxaparin

Participants

14

Sites

1

Countries

Germany

Trials that died the same way

• CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
  “The pharmaceutical funder pulled funding and no longer plans to develop the drug further.” (68% match in meaning)
• Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
  “While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.” (65% match in meaning)
• Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH
  “Funding was stopped” (65% match in meaning)
• Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography
  “Funding for the study could not be obtained.” (63% match in meaning)
• Safety Study of Nebivolol for COPD Patients
  “Funding was discontinued.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.